New 'Living Drug' trial aims to fight tough blood cancers
NCT ID NCT07234045
Summary
This early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy called CT1195E. It is for adults with B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia that has come back or not responded to standard treatments. Researchers will give patients a single infusion of these genetically modified immune cells and closely monitor how their bodies respond.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, Tianjin Municipality, 301617, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.